Last Updated : July 3, 2024
Details
Generic Name:
tarlatamab
Project Status:
Pending
Therapeutic Area:
Extensive stage small cell lung cancer
Manufacturer:
Amgen Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0351-000
Call for patient/clinician input closed:
Tumour Type:
Lung
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of adult
patients with extensive stage small cell lung cancer (ES-SCLC) with disease
progression on or after at least two prior lines of therapy including
platinum-based chemotherapy.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : July 3, 2024